Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Ginkgo Bioworks reports mixed Q3 results, focuses on growth strategies

Ginkgo Bioworks showed strength in cost-cutting, revenue generation, and strategic focus, despite a negative adjusted EBITDA.
Challenges include financial pressures, margin concerns, and potential risks in resource utilization and funding stability.
Opportunities lie in new offerings, AI capabilities, market expansion, and revenue scale for improved profitability.
Management's emphasis on cost reduction, revenue growth, and innovation positions the company for long-term success and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BitNile Holdings

Sorrento Therapeutics Inc

Check these three penny stocks out as the stock market falls The post 3 Penny Stocks to Watch During the Stock Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks to Watch During the Stock Market Crash

CRISPR Therapeutics

Novocure

These stocks are losers now. But they could be huge winners over the next few years.

3 Beaten-Down Stocks That Could Deliver 5X Gains By 2030

Archer Aviation

Atai Life Sciences BV

Cerus

Compugen

Joby Aviation

Nano Dimension

Invitae

Quantum-Si

Zymergen

Are these Cathie Wood penny stocks a buy right now? The post 10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?

10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?

DNA stock is in the spotlight after Ark Invest reported purchasing more than 1.5 million shares this week. So, who else is betting big on Ginkgo?

Cathie Wood Keeps Buying Gingko Bioworks (DNA) Stock. Here's Why.

Cazoo Group Ltd

Lottery.com

Netflix

Novavax

Shopify

Sonder Holdings

While going contrarian is always a risky concept, these biggest loser stocks could bounce higher with the negativity priced in. The post 7 Biggest Loser Stocks That Could Become Surprising Buys appeared first on InvestorPlace.

7 Biggest Loser Stocks That Could Become Surprising Buys

Planned transaction expands Ginkgo's horizontal platform capabilities to support agricultural biologicals R&D from discovery through formulation and early field trials and will offer services to customers of all sizes in the agriculture industry Under the proposed transaction, Ginkgo to acquire Bayer's West Sacramento agricultural biologicals site and team, adding a 175,000-square-foot R&D facility with pilot scale fermentation, formulation, and greenhouse facilities, along with access to Bayer's large agricultural strain collection Joyn Bio, the joint-venture between Ginkgo and Leaps by Bayer formed in 2017, to be integrated into the parent companies, with the core technology platform becoming part of Ginkgo's platform and key products being advanced by Bayer in a new collaboration Bayer to be an anchor customer of Ginkgo's agricultural biologicals offering, signing a follow-on multi-year platform collaboration deal to enable continued development of Joyn Bio's flagship nitrogen fixation program and launching new programs in fields including next-generation crop protection and carbon sequestration BOSTON , April 22, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced plans to significantly expand its platform capabilities in agricultural biologicals, from discovery to field. These capabilities will be built through a series of transactions, in which Ginkgo will acquire Bayer's 175,000-square-foot West Sacramento Biologics Research & Development site, team, and internal discovery and lead optimization platform as well as integrate the R&D platform assets from Joyn Bio, a joint-venture between Ginkgo and Leaps by Bayer formed in 2017.

Ginkgo Bioworks to Expand Platform Capabilities in Agricultural Biologicals and Launch Flagship Partnership with Bayer

Bayer AG

MONHEIM, Germany--(BUSINESS WIRE)--Bayer today announced that the company is pursuing an agreement whereby Ginkgo Bioworks will acquire Bayer's West Sacramento Biologics Research & Development (R&D) site and internal discovery and lead optimization platform. The contemplated transaction, projected to close before the end of 2022 pending final negotiation of the agreement terms and subject to regulatory approvals, would also bring Joyn Bio's nitrogen-fixing technologies to Bayer, success

Bayer to Create Ag Biologicals Powerhouse Partnership with Ginkgo Bioworks, Advancing Joyn Bio Technology Platforms

Leveraging Ginkgo's plant-cell assay and engineering capabilities to aid Light Bio in optimizing the performance of its light-emitting plants KETCHUM, Idaho and BOSTON , April 14, 2022 /PRNewswire/ -- Light Bio, Inc., a company that is creating bioluminescent plants for home and garden, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to leverage Ginkgo's plant cell assays for bioluminescence engineering. Through the agreement, Ginkgo aims to help improve the luminescent output and efficiency of the enzymes within Light Bio's glowing ornamental plants.

Light Bio Partners with Ginkgo Bioworks to Optimize the Brightness of Glowing Plants through Bioluminescence Engineering

Biotechnology company Ginkgo Bioworks has a host of promising collaboration announcements. DNA stock is up as a result.

Why Is Ginkgo Bioworks (DNA) Stock Up Today?

FREDsense will leverage Ginkgo's strain development platform capabilities to develop advanced biosensors capable of detecting harmful molecules and toxins in any water source CALGARY, Canada and BOSTON , April 13, 2022 /PRNewswire/ -- FREDsense Technologies Corp , a next generation water quality platform company leveraging synthetic biology to build field kits for faster, cheaper, and more efficient analysis, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a partnership to build biosensors for water quality monitoring and detection. Through this partnership, Ginkgo seeks to build four distinct microbial strain biosensors, compatible with FREDsense's field-ready hardware for remote water quality monitoring applications.

FREDsense and Ginkgo Bioworks Announce Partnership to Develop Water Quality Biosensors

Multi-project agreement involves engineering of anaerobic species, a critical component for microbiome medicines SAN DIEGO and BOSTON , April 12, 2022 /PRNewswire/ -- Persephone Biosciences Inc. , a synthetic biology company reimagining patient and infant health, and Ginkgo Bioworks  (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to develop a novel therapeutics based on the bacterial genus Bacteroides. Bacteroides species are among the most common members of the microbiota of animals, especially in the gastrointestinal tract, and are likely a useful tool for stable and long-term delivery of microbial medicines.

Persephone Biosciences and Ginkgo Bioworks Announce Collaboration to Develop Novel Therapeutics

Elanco Animal Health Inc

Elanco Animal Health Incorporated (NYSE: ELAN) and Ginkgo Bioworks Holdings Inc (NYSE: DNA) have launched BiomEdit, a microbiome innovation company. BiomEdit will discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines, and.

Elanco, Ginkgo Bioworks Launch BiomEdit, Microbiome-Focused Animal Health Firm

Baillie Gifford recently disclosed that it purchased 48.8 million shares of DNA stock on March 31. The firm has a $180 billion portfolio.

Baillie Gifford Just Bought Ginkgo Bioworks (DNA) Stock. Here's Why.

Twist Bioscience Corp

SOUTH SAN FRANCISCO, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a new supply agreement expanding the depth and breadth of the collaboration between two of the leading organizations in the synthetic biology ecosystem. The four-year agreement

Twist Bioscience and Ginkgo Bioworks Sign New Collaboration

Partnership will leverage Ginkgo's high throughput screening capabilities to identify potential therapeutic candidates for autoimmune diseases in Microba's extensive strain bank BRISBANE, Australia and BOSTON , April 4, 2022 /PRNewswire/ -- Microba Life Sciences (ASX:MAP), a precision microbiome science company, and Ginkgo Bioworks  (NYSE: DNA), the leading horizontal platform for cell programming, today announced a partnership to identify single-strain, live bacteria product (LBP) candidates against autoimmune diseases. The collaboration aims to build on Microba's precision approach to LBP development with an in-depth evaluation of the company's strains using Ginkgo's high throughput, automated screening capabilities.

Microba Life Sciences and Ginkgo Bioworks Announce Partnership to Discover Novel Live Biotherapeutics

You'll have to put in some work to appreciate this stock's alluring nuances.

3 Things About Ginkgo Bioworks That Smart Investors Know

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher by 22.0% at $4.56 after the company reported better-than-expected fourth-quarter sales results and issued FY22 sales guidance above analyst estimates. Ginkgo Bioworks reported quarterly sales of $148.00 million which beat the.

Here's Why Ginkgo Bioworks Shares Are Rising

Investors applauded the company's Q4 update.

Why Ginkgo Bioworks Stock Is Jumping Today

DNA stock is bouncing higher following a better-than-expected earnings report and strong forward guidance from Gingko Bioworks. The post Is DNA Stock a Buy After Earnings?

Is DNA Stock a Buy After Earnings? 3 Analysts Weigh In on Gingko Bioworks.

Ginkgo Bioworks Holdings Inc (NYSE: DNA) reported Q4 FY21 sales of $148.5 million, up 363% Y/Y, beating the consensus of $94.81 million. "The current market environment provides challenges and opportunities, but I've never been more excited about Ginkgo's future," said.

Ginkgo Bioworks Shares Gain As Q4 Sales, FY22 Guidance Surpass Street Expectations

Ginkgo Bioworks Holdings, Inc. (DNA) CEO Jason Kelly on Q4 2021 Results - Earnings Call Transcript

Ginkgo Bioworks Holdings Inc (NYSE: DNA) is trading higher in Monday's after-hours session after the company reported financial results and issued guidance above estimates.  Ginkgo Bioworks said fourth-quarter revenue increased 363% year-over-year to $148 million, which beat the $94.

Why Ginkgo Bioworks Stock Is Rising After Hours

$314 million of Total revenue in 2021, representing an increase of 309% over 2020 31 new Cell Programs added in 2021, representing 72% growth over 2020 Over $1.5 billion cash balance, providing meaningful multi-year runway as we drive towards profitability BOSTON , March 28, 2022 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), the leading horizontal platform for cell programming, today announced its results for the fourth quarter and year ended December 31, 2021. The update, including a webcast slide presentation with additional details on the fourth quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results

Ginkgo Bioworks Holdings is a biotech company operating in a rapidly growing industry.

Ginkgo Bioworks: A Biotech Buy Opportunity With Incoming Growth Potential

Bionano Genomics

Vaxart

These stocks are all about cutting-edge technology.

News for Ginkgo Bioworks Holdings Stock (DNA)